Description: COVID-19 pandemic has highlighted developing countries’ vulnerability due to their reliance on imports for most vaccines and medicines. This is a direct consequence of the lack of local vaccine manufacturing capacity (drug product and fill&finish). The presented Stevanato Group’s ready-to-use drug containment solutions platform helps pharmaceutical companies and their CMO to speed up the installation of fill&finish capacity for vaccines and reduce the Total Cost of Ownership ensuring the highest level of integrity and safety of the drug product.
Topics to be discussed:
- Local requirements for fill&finish vaccine manufacturing in developing countries
- Ready to use drug containment solutions to meet current and future needs of vaccine manufacturers in developing countries
- Reduce capital expenditure
- Reduce timelines for fill&finish capacity installation and expansion
- Reduce complexity in operations and the need of qualified operators
- Reduction of utility consumption (including WFI)
- Superior integrity and safety of the drug product
- Compliance with EU and US quality and regulatory requirements and guidelines to export in these markets
- Reduce Total Cost of Ownership
